CEO Gaffe of the Week: Bristol-Myers Squibb -- Again!
This year, I introduced a weekly series called "CEO Gaffe of the Week." Having come across more than a handful of questionable executive decisions last year when compiling my list of the worst CEOs of 2011, I thought it could be a learning experience for all of us if I pointed out apparent gaffes as they occur. Trusting your investments begins with trusting the leadership at the top -- and with leaders like these on your side, sometimes you don't need enemies!
This week I want to highlight, once again, Bristol-Myers Squibb (NYS: BMY) CEO Lamberto Andreotti and focus on what has been an abysmal month for the company.
The dunce cap
Who would have thought that paying $2.5 billion for an experimental hepatitis-C drug that was barely out of phase 1 clinical trials would be a bad idea? Oh yeah, that's right: I did -- in January, March, April, and May.
I was shaking my head in dismay in January when Bristol ponied up $2.5 billion for Inhibitex -- a move preempted by Gilead Sciences' (NAS: GILD) aggressive $11 billion purchase of Pharmasset. However, since that purchase, things have gone in completely divergent paths for the two hepatitis-C hopefuls. Gilead's GS7977 has demonstrated incredible efficacy and tolerability among patients, and (thankfully for Bristol shareholders) it has also worked well as a combination therapy with Bristol-Myers' daclatasvir.
Bristol's drug, on the other hand...not so great. BMS-986094 (the hepatitis-C drug it acquired when Bristol purchased Inhibitex) was suspended earlier this month after a patient suffered a cardiac event that eventually led to death. Since that time, Bristol has completely discontinued the drug, outlined plans to take a $1.8 billion writedown on its investment, and noted that nine additional patients were in need of hospitalization due to complications from BMS-986094.
It's not bad enough that Andreotti steered his ship into a clearly visible iceberg, but his drugs' failure has aimed his sinking ship at his peers as well. Since BMS-986094 worked as a nucleotide inhibitor, other nucleotide-based treatments are now under severe scrutiny. Idenix Pharmaceuticals (NAS: IDIX) has had not one, but two clinical holds placed on hepatitis-C drugs in its pipeline by the Food and Drug Administration due to safety concerns in the past two weeks. Similarly, Gilead's share price suffered briefly as it, too, is a nucleotide-based inhibitor. Only Achillion Pharmaceuticals (NAS: ACHN) and Vertex Pharmaceuticals (NAS: VRTX) seemed to escape Bristol's aimless careening. Achillion's mid-stage hepatitis-C hopeful, ACH-1625, and Vertex Pharmaceuticals' VX-222 are non-nucleotide inhibitors that aren't on the FDA's safety concern radar (at least not right now). Vertex also received a boost from Bristol's failure, as it means added safety for its premiere interferon-based hepatitis-C treatment, Incivek.
To the corner, Mr. Andreotti
So Lamberto Andreotti made an awful buy. It couldn't get worse than that, could it?
Oh, yes, it could!
In addition to shelving its premiere hepatitis-C drug, Bristol-Myers has also dealt with a drug recall and an executive insider-trading scandal just this month. Just yesterday Bristol disclosed a 31,000-unit recall of carmustine, a drug used to treat various types of cancers, after it discovered an overfilled vial which could lead to potential overdoses of the drug. In Bristol's defense, no adverse patient reactions have been reported thus far.
What's both sad and comical is the insider trading allegations brought against Bristol insider Robert D. Ramnarine, who profited more than $300,000 from front-running stock and call purchases in companies he was advising Bristol-Myers to buy. Not only was he caught, but the Securities and Exchange Commission noted that he used Bristol's own computers to research whether or not he'd be caught and viewed articles on how to avoid getting caught for insider trading. What I wouldn't give for a thumbs-up icon right now!
So while this is going on at Bristol, Lamberto Andreotti is getting a 27% raise! In March, Andreotti had his compensation packaged boosted to $14.8 million for delivering strong results and working toward its "string of pearls" strategy of acquiring new drugs. I'm curious how well that'll go over next year with a $1.8 billion boo-boo on the books and that pearl strand now in knots. What's more, Andreotti's pay raise came almost immediately after a one-year freeze on all workers' compensation had been lifted.
Seriously, I couldn't make this up if I tried. Andreotti joins a short list of CEOs who have appeared in this column twice, and I can't say for certain -- even now -- whether this will be his last visit to the futility column.
Do you have a CEO you'd like to nominate for this dubious honor? Shoot me an email and a one- or two-sentence description of why your choice deserves next week's nomination, and you just may see your suggestion in the spotlight.
If you'd like a surefire way to avoid investing in companies with questionable leadership practices, I invite you to download a copy of our latest special report: "Secure Your Future With 9 Rock-Solid Dividend Stocks." This report contains a wide array of companies and sectors that are likely to keep your best interests in mind, regardless of whether the market is up or down. Best of all, it's completely free for a limited time, so don't miss out!
The article CEO Gaffe of the Week: Bristol-Myers Squibb -- Again! originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. He is merciless when it comes to poking fun at dubious CEO antics. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that never wears a dunce cap.